MIR9-1: Potential Drug Target and Biomarker for Cancer (G407046)

Target Name: MIR9-1

NCBI ID: G407046

MIR9-1

MIR9-1: Potential Drug Target and Biomarker for Cancer

MIR9-1, also known as mir-9-1, is a protein that is expressed in various tissues of the body, including the lungs, heart, kidneys, and intestines. It is a key regulator of cell growth and differentiation, and has been identified as a potential drug target in the field of oncology.

MIR9-1 is a transmembrane protein that is composed of an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain is involved in the protein's stability and functions as a receptor. The transmembrane domain is responsible for the protein's ability to interact with other molecules on the cell surface. The intracellular domain is responsible for the protein's ability to interact with and regulate the activity of intracellular signaling pathways.

MIR9-1 has been shown to play a role in a variety of cellular processes, including cell growth, differentiation, and survival. It has been shown to promote the growth and survival of cancer cells, and has been identified as a potential drug target in the field of oncology.

One of the most promising aspects of MIR9-1 is its potential as a drug target is its involvement in the regulation of cell growth and differentiation. MIR9-1 has been shown to play a role in the regulation of cell proliferation, and has been shown to promote the growth and survival of cancer cells. This makes it a promising target for cancer therapies that aim to inhibit cell growth and proliferation.

Another promising aspect of MIR9-1 is its involvement in the regulation of cellular signaling pathways. MIR9-1 has been shown to play a role in a variety of cellular signaling pathways, including the TGF-β pathway. This pathway is involved in the regulation of cell growth, differentiation, and survival, and has been implicated in the development and progression of many diseases, including cancer.

MIR9-1 has also been shown to play a role in the regulation of inflammation. It has been shown to be involved in the regulation of the immune response, and has been implicated in the development of many inflammatory diseases. This makes it a promising target for therapies that aim to alleviate inflammation and its associated diseases.

In addition to its potential as a drug target, MIR9-1 has also been shown to have a variety of potential therapeutic applications. For example, it has been shown to be involved in the regulation of cell migration, which is involved in the development of many diseases, including cancer. This makes it a promising target for therapies that aim to inhibit cell migration and its associated diseases.

MIR9-1 is also a good candidate for a biomarker in the field of oncology. Its involvement in the regulation of cell growth, differentiation, and signaling pathways makes it a promising indicator of the effectiveness of certain therapies. This could be used to monitor the effectiveness of cancer therapies and identify potential biomarkers for the treatment of cancer.

In conclusion, MIR9-1 is a protein that has been shown to play a role in a variety of cellular processes, including cell growth, differentiation, and signaling pathways. Its involvement in these processes makes it a promising target for cancer therapies, as well as a potential biomarker for the treatment of cancer. Further research is needed to fully understand the role of MIR9-1 in cellular processes and its potential as a drug target and biomarker.

Protein Name: MicroRNA 9-1

The "MIR9-1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR9-1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets